Malvern, PA, September 3, 2015 — PhaseBio Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company and leader in the field of biopolymer-based drugs focused on developing treatments for metabolic and specialty cardiopulmonary disorders, today announced that Chief Executive Officer Jonathan P. Mow will present a company overview at the Rodman & Renshaw 17th Annual Global Investment Conference on Thursday, September 10 at 3:50 p.m. EDT at the St. Regis Hotel in New York City.
For more information about the conference, please visit:
PhaseBio Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company developing novel drugs to treat diabetes and cardiovascular dysfunction in patients suffering from rare diseases. The Company’s proprietary discovery platform technology uses recombinant ELP biopolymers to control the half-life, bioavailability and physical characteristics of molecules for ease of administration. The resulting compounds are tuned for a specific rate of absorption, thereby increasing efficacy and reducing side effects. The Company’s lead development candidates are PE0139, a novel super-long-acting basal insulin-ELP fusion for weekly dosing; and PB1046, a weekly VIP receptor agonist for treatment and prevention of cardiomyopathy due to a loss of dystrophin in patients with X-linked cardiomyopathy, Duchenne and Becker muscular dystrophy, and for the treatment of acute and chronic heart failure. PhaseBio is privately owned, with headquarters and research laboratories in Malvern, PA.